Matches in Ghent University Academic Bibliography for { <https://biblio.ugent.be/publication/01GQFBRQ1QM7EKWG28DM7T4DWR> ?p ?o. }
Showing items 1 to 23 of
23
with 100 items per page.
- 01GQFBRQ1QM7EKWG28DM7T4DWR classification A1.
- 01GQFBRQ1QM7EKWG28DM7T4DWR date "2022".
- 01GQFBRQ1QM7EKWG28DM7T4DWR language "eng".
- 01GQFBRQ1QM7EKWG28DM7T4DWR type journalArticle.
- 01GQFBRQ1QM7EKWG28DM7T4DWR hasPart 01GQFCDZCPSTKQV30XC9ESX2T6.pdf.
- 01GQFBRQ1QM7EKWG28DM7T4DWR subject "Medicine and Health Sciences".
- 01GQFBRQ1QM7EKWG28DM7T4DWR doi "10.3390/diagnostics12123092".
- 01GQFBRQ1QM7EKWG28DM7T4DWR issn "2075-4418".
- 01GQFBRQ1QM7EKWG28DM7T4DWR issue "12".
- 01GQFBRQ1QM7EKWG28DM7T4DWR volume "12".
- 01GQFBRQ1QM7EKWG28DM7T4DWR abstract "A mucormycosis surge was reported during the COVID-19 pandemic in India. A literature search until 14 July 2022, with the aim of updating COVID-19-associated mucormycosis (CAM), identified 663 studies and 88 met inclusion criteria (8727 patients). India reported 8388 patients, Egypt 208 and Europe 40. Rhino-orbito-cerebral mucormycosis (ROCM) was identified among 8082 (98.3%) patients, followed by 98 (1.2%) with pulmonary. In India, 82.6% of patients had diabetes mellitus, with 82% receiving corticosteroids. In Europe, 75% presented pulmonary CAM, 32.5% had diabetes and 40% were immunocompromised. CAM was identified at a median of 17.4 days (IQR 7.5 days) post COVID-19 diagnosis, and PCR was performed in five studies. Rhino-orbital invasion is clinically obvious, while cerebral involvement presents with cavernous sinus thrombosis, meningitis and cerebrovascular disease. Symptoms of pulmonary CAM usually overlap with severe COVID-19 pneumonia. High-dose liposomal Amphotericin B (and early surgical debridement in ROCM) are the mainstay of therapy. The median mortality rate was estimated to be 21.4% (IQR 31.9%), increased by the presence of pulmonary (80% (IQR 50%) or cerebral involvement (50% (IQR 63.9%). In summary, different CAM clinical phenotypes need to be distinguished, influenced by geographical presentation. Opportunities exist for diagnosis and therapy optimization, based on earlier high-dose antifungal therapy, early source control, strict glycemic control and restriction of steroids to COVID-19 patients with oxygen requirements.".
- 01GQFBRQ1QM7EKWG28DM7T4DWR author F63D780A-F0ED-11E1-A9DE-61C894A0A6B4.
- 01GQFBRQ1QM7EKWG28DM7T4DWR author urn:uuid:26d2be2f-5ea2-47cf-8f5f-299c98465a52.
- 01GQFBRQ1QM7EKWG28DM7T4DWR author urn:uuid:3b33988e-71ed-4163-b8fd-ed1daac460ad.
- 01GQFBRQ1QM7EKWG28DM7T4DWR author urn:uuid:3dae2d8f-4b4f-4c9d-b6e6-4cf9a5928468.
- 01GQFBRQ1QM7EKWG28DM7T4DWR author urn:uuid:76891193-da43-45ad-bc1d-a299fb14c5e1.
- 01GQFBRQ1QM7EKWG28DM7T4DWR dateCreated "2023-01-23T13:06:04Z".
- 01GQFBRQ1QM7EKWG28DM7T4DWR dateModified "2024-07-09T07:43:20Z".
- 01GQFBRQ1QM7EKWG28DM7T4DWR name "Clinical phenotypes of COVID-19 associated mucormycosis (CAM) : a comprehensive review".
- 01GQFBRQ1QM7EKWG28DM7T4DWR pagination urn:uuid:4b15ef27-11a5-4463-84fc-6857a0ab9f56.
- 01GQFBRQ1QM7EKWG28DM7T4DWR sameAs LU-01GQFBRQ1QM7EKWG28DM7T4DWR.
- 01GQFBRQ1QM7EKWG28DM7T4DWR sourceOrganization urn:uuid:c6fea136-55ee-4a06-b917-e9732f17e834.
- 01GQFBRQ1QM7EKWG28DM7T4DWR type A1.